Krajina: Írsko
Jazyk: angličtina
Zdroj: HPRA (Health Products Regulatory Authority)
Azelastine hydrochloride; Fluticasone propionate
IMED Healthcare Ltd.
R01AD; R01AD58
Azelastine hydrochloride; Fluticasone propionate
137/50 µg/actuation
Nasal spray, suspension
Corticosteroids; fluticasone, combinations
2017-10-27
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT DYMISTA 137 MICROGRAMS / 50 MICROGRAMS PER ACTUATION, NASAL SPRAY, SUSPENSION Azelastine hydrochloride/fluticasone propionate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Dymista is and what it is used for 2. What you need to know before you use Dymista 3. How to use Dymista 4. Possible side effects 5. How to store Dymista 6. Contents of the pack and other information 1. WHAT DYMISTA IS AND WHAT IT IS USED FOR Dymista contains two active substances: azelastine hydrochloride and fluticasone propionate. • Azelastine hydrochloride belongs to a group of medicines called antihistamines. Antihistamines work by preventing the effects of substances such as histamine that the body produces as part of an allergic reaction – thus reducing symptoms of allergic rhinitis. • Fluticasone propionate belongs to a group of medicines called corticosteroids which reduces inflammation. Dymista is used to relieve the symptoms of moderate to severe seasonal and perennial allergic rhinitis if the use of either intranasal antihistamine or corticosteroid alone is not considered sufficient. Seasonal and perennial allergic rhinitis are allergic reactions to substances such as pollen (hayfever), house mites, moulds, dust or pets. Dymista relieves the symptoms of allergies, for example: runny nose, post nasal drip, sneezing and itchy or blocked nose. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE DYMISTA DO NOT USE DYMISTA: • If you are allergic to azelastine hydrochlor Prečítajte si celý dokument
Health Products Regulatory Authority 25 September 2023 CRN00DV97 Page 1 of 2 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Dymista 137 micrograms/50 micrograms per actuation nasal spray, suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each g of suspension contains 1000 micrograms azelastine hydrochloride and 365 micrograms fluticasone propionate. Each actuation (0.14 g) delivers 137 micrograms azelastine hydrochloride (equivalent to 125 micrograms azelastine) and 50 micrograms fluticasone propionate. Excipient with known effect: Benzalkonium chloride For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Nasal Spray Suspension _Product imported from France _ White, homogenous suspension. 4 CLINICAL PARTICULARS As per PA23355/010/001 5 PHARMACOLOGICAL PROPERTIES As per PA23355/010/001 6 PHARMACEUTICAL PARTICULARS 6.1 LIST OF EXCIPIENTS Disodium edetate Glycerol Microcrystalline cellulose Carmellose sodium Polysorbate 80 Benzalkonium chloride Phenylethyl alcohol Purified water 6.2 INCOMPATIBILITIES Not applicable 6.3 SHELF LIFE The shelf life expiry date of this product is the date shown on the bottle and outer carton of the product as marketed in the country of origin. In-use shelf life (after first use): 6 months Health Products Regulatory Authority 25 September 2023 CRN00DV97 Page 2 of 2 6.4 SPECIAL PRECAUTIONS FOR STORAGE Do not refrigerate or freeze. 6.5 NATURE AND CONTENTS OF CONTAINER Cardboard outer carton containing an amber coloured glass bottle fitted with a spray pump, applicator and a protective cap. Pack size: 1 bottle with 23 g suspension in 25 ml bottles (at least 120 actuations) 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING No special requirements for disposal. 7 PARALLEL PRODUCT AUTHORISATION HOLDER IMED Healthcare Ltd. Unit 625 Kilshane Avenue Northwest Business Park Ballycoolin Dublin 15 Ireland 8 PARALLEL PRODUCT AUTHORISATION NUMBER PPA1463/151/001 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 27 th Prečítajte si celý dokument